Pharmacological characterization of [3H]‐prostaglandin E2 binding to the cloned human EP4 prostanoid receptor
- 1 August 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 130 (8) , 1919-1926
- https://doi.org/10.1038/sj.bjp.0703525
Abstract
Prostaglandin (PG) E(2) (PGE(2)) is a potent prostanoid derived from arachidonic which can interact with EP(1), EP(2), EP(3) and EP(4) prostanoid receptor subtypes. Recombinant human EP(4) receptors expressed in human embryonic kidney (HEK-293) cells were evaluated for their binding characteristics using [(3)H]-PGE(2) and a broad panel of natural and synthetic prostanoids in order to define their pharmacological properties. [(3)H]-PGE(2) binding was optimal in 2-[N-Morpholino]ethanesulphonic acid (MES) buffer (pH 6.0) yielding 98+/-0.7% specific binding. The receptor displayed high affinity (K(d)=0.72+/-0.12 nM; n=3) for [(3)H]-PGE(2) and interacted with a saturable number of binding sites (B(max)=6.21+/-0.84 pmol mg(-1) protein). In competition studies, PGE(2) (K(i)=0.75+/-0.03 nM; n=12) and PGE(1) (K(i)=1.45+/-0.24 nM; n=3) displayed high affinities, as did two derivatives of PGE(1), namely 11-deoxy-PGE(1) (K(i)=1.36+/-0.34 nM) and 13,14-dihydro-PGE(1) (K(i)=3.07+/-0.29 nM). Interestingly, synthetic DP receptor-specific agonists such as BW245C (K(i)=64.7+/-1.0 nM; n=3) and ZK118182 (K(i)=425+/-42 nM; n=4), and the purported EP(3) receptor-specific ligand enprostil (K(i)=43.1+/-4.4 nM), also displayed high affinity for the EP(4) receptor. Two known EP(4) receptor antagonists were weak inhibitors of [(3)H]-PGE(2) binding akin to their known functional potencies, thus: AH23848 (K(i)=2690+/-232 nM); AH22921 (K(i)=31,800+/-4090 nM). These studies have provided a detailed pharmacological characterization of the recombinant human EP(4) receptor expressed in HEK-293 cells.Keywords
This publication has 38 references indexed in Scilit:
- Endogenous EP4prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterizationProstaglandins, Leukotrienes & Essential Fatty Acids, 2000
- Quantitative Autoradiographic Visualization and Pharmacology of FP-Prostaglandin Receptors in Human Eyes Using the Novel Phosphor-Imaging TechnologyJournal of Ocular Pharmacology and Therapeutics, 1999
- [3H]AL-5848 ([3H]9β-(+)-Fluprostenol). Carboxylic Acid of Travoprost (AL-6221), a Novel FP Prostaglandin o study the Pharmacology and Autoradiographic Localization of the FP ReceptorJournal of Pharmacy and Pharmacology, 1999
- Increased PGE2 Production Mediates the In Vitro Inhibitory Effect of the Human Immunodeficiency Virus P24 Immunosuppressive Heptapeptide Ch7Scandinavian Journal of Immunology, 1998
- Characterization of the recombinant human prostanoid DP receptor and identification of L‐644,698, a novel selective DP agonistBritish Journal of Pharmacology, 1998
- Characterization of [3H]‐prostaglandin E2 binding to prostaglandin EP4 receptors expressed with Semliki Forest virusBritish Journal of Pharmacology, 1997
- Nonlinear regression using spreadsheetsTrends in Pharmacological Sciences, 1995
- Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.British Journal of Ophthalmology, 1992
- A practical computer-based approach to the analysis of radioligand binding experimentsComputer Programs in Biomedicine, 1983
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973